Immunoprevention of cancer: time to reconsider timing of vaccination against cancer.
Spisek
Radek
R
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016147:Genes, Tumor Suppressor; D020022:Genetic Predisposition to Disease; D006801:Humans; D007115:Immunization Schedule; D016867:Immunocompromised Host; D007167:Immunotherapy; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy; D009374:Neoplasms, Experimental / Q000235:genetics / Q000276:immunology / Q000517:prevention & control; D009857:Oncogenes; D011230:Precancerous Conditions / Q000175:diagnosis / Q000628:therapy; D012306:Risk; D014611:Vaccination
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines